| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
33,094 |
26,667 |
$2.55M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
11,106 |
9,981 |
$883K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
6,332 |
5,749 |
$220K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
8,395 |
7,388 |
$128K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,008 |
2,802 |
$109K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
768 |
731 |
$97K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
260 |
249 |
$89K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,789 |
1,664 |
$69K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,702 |
1,788 |
$29K |
| 36410 |
|
1,505 |
1,150 |
$22K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
305 |
299 |
$15K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,241 |
950 |
$14K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
381 |
373 |
$12K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
364 |
338 |
$9K |
| 81002 |
|
2,728 |
2,386 |
$7K |
| 93000 |
|
296 |
275 |
$6K |
| 71046 |
Radiologic examination, chest; 2 views |
328 |
310 |
$5K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
72 |
71 |
$5K |
| 87807 |
|
486 |
438 |
$5K |
| 73610 |
|
185 |
165 |
$5K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
81 |
80 |
$4K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,782 |
1,183 |
$4K |
| 73630 |
|
149 |
128 |
$3K |
| 81025 |
|
473 |
428 |
$3K |
| 87420 |
|
112 |
109 |
$2K |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
132 |
86 |
$2K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
164 |
128 |
$1K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
83 |
83 |
$1K |
| 86308 |
|
214 |
172 |
$991.64 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
44 |
28 |
$659.38 |
| 73140 |
|
25 |
24 |
$496.05 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
254 |
173 |
$484.04 |
| 87486 |
|
12 |
12 |
$421.08 |
| 87581 |
|
12 |
12 |
$421.08 |
| 73110 |
|
14 |
12 |
$310.80 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
26 |
14 |
$307.21 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
52 |
39 |
$268.35 |
| 73562 |
|
12 |
12 |
$249.76 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
1,283 |
953 |
$194.99 |
| 81000 |
|
63 |
39 |
$162.44 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
67 |
44 |
$70.27 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
21 |
12 |
$7.11 |